• SAB Biotherapeutics set June conference presentations on SAB-142, its lead immunotherapy in development for newly diagnosed Stage 3 type 1 diabetes.
• Results have not been presented yet; management pointed to new safety and repeat-dosing findings, pharmacology signals, and mechanistic readouts.
• Data are positioned to support SAB-142’s potential as a redosable, disease-modifying approach, a key differentiation for longer-term treatment use.
• The company is running the registrational Phase 2b SAFEGUARD study, with a topline readout targeted for 2H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief on May 29, 2026, and is solely responsible for the information contained therein.